CGTX COGNITION THERAPEUTICS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1455365 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY42.9%
TTM EPS YoY66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.6%
ROA-40.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets15.9%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.12M | $5.10M | $6.12M | $11.15M | $3.77M | $11.48M | $10.79M | $8.15M |
| SG&A expense | $2.25M | $2.64M | $2.70M | $2.52M | $2.60M | $2.50M | $2.99M | $2.57M |
| Operating income | -$7.38M | -$7.74M | -$8.82M | -$13.67M | -$6.38M | -$13.98M | -$13.78M | -$10.72M |
| Net income | -$4.14M | -$3.93M | -$4.57M | -$3.34M | -$4.93M | -$6.73M | -$8.48M | -$7.84M |
| EBITDA | — | — | — | -$13.66M | -$6.36M | — | — | -$10.70M |
| EPS (basic) | -0.04 | -0.04 | -0.05 | — | -0.06 | -0.11 | -0.14 | — |
| EPS (diluted) | -0.04 | -0.04 | -0.05 | — | -0.06 | -0.11 | -0.14 | — |
| Weighted avg. shares (diluted) | 95.10M | 90.62M | 89.19M | — | 77.95M | 63.69M | 61.83M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $30.76M | $34.01M | $31.13M | $36.81M | $39.33M | $10.74M | $16.43M | $25.01M |
| Current assets | $34.24M | $38.30M | $35.81M | $47.99M | $42.88M | $19.05M | $22.87M | $29.55M |
| PP&E, net | $76,000 | $87,000 | $77,000 | $93,000 | $159,000 | $174,000 | $190,000 | $181,000 |
| Total assets | $34.80M | $38.90M | $36.14M | $48.39M | $43.40M | $19.62M | $23.50M | $30.23M |
| Current liabilities | $5.13M | $5.45M | $6.05M | $13.92M | $6.65M | $12.36M | $10.95M | $11.14M |
| Total liabilities | $5.53M | $5.87M | $6.23M | $14.12M | $6.87M | $12.59M | $11.23M | $11.48M |
| Shareholders' equity | $29.28M | $33.02M | $29.91M | $34.27M | $36.53M | $7.03M | $12.27M | $18.75M |
| Shares outstanding | 95.10M | 95.06M | 89.35M | 88.90M | 88.27M | 64.96M | 61.97M | 59.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.26M | -$3.05M | -$5.54M | -$3.44M | -$5.65M | -$5.62M | -$9.88M | -$8.38M |
| Capital expenditure | $0 | — | — | — | — | — | — | $1,000 |
| Free cash flow | -$3.26M | — | — | — | — | — | — | -$8.38M |
| Investing cash flow | $0 | — | — | — | — | — | — | -$1,000 |
| Financing cash flow | -$28,000 | $6.61M | -$233,000 | $605,000 | $33.92M | $752,000 | $1.30M | $11.38M |
| Depreciation & amortization | — | — | — | $14,000 | $15,000 | — | — | $27,000 |
| Stock-based compensation | $348,000 | $319,000 | $330,000 | $358,000 | $522,000 | $621,000 | $586,000 | $534,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.